The South San Francisco biotech startup, Denali Therapeutics, that had raised $217 million last year to fight Alzheimer’s, Parkinson’s and ALS, and an additional $130 million from investors in a private placement led by Baillie Gifford, a UK-based mutual fund, has finally spoken about its plans to use the fund. The company is based to discover genes that have been implicated in the diseases mentioned. This project is the one that Denali’s CEO and co-founder, Ryan Watts was working on while at Genentech. The project is related to the LRRK2 gene, which is implicated in Parkinson’s disease. Many companies were working to develop drugs for it, when it was then discovered that those drugs seemed to cause lung problems in animals. Watts is of the opinion that the dosing needs to be adjusted, where the drug would block LRRK2 without causing the lung issues. Apart from this drug compound, Denali is working on others as well. On August 22, 2016, Denali filed an application in Europe to start a clinical trial in healthy volunteers for testing a new drug which is aimed at Alzheimer’s disease and Amyotrophic Lateral Sclerosis (ALS). The company is also working on drugs focused on the APOE genes. These genes are involved in the cholesterol processing in the human body and, are seen to be a key risk factor for Alzheimer’s. Denali also has a research collaboration with F-Star, a UK-based company, to deliver drugs across the blood-brain barrier that keeps medicines from getting into brain tissue.
- Top Artificial Intelligence-Based Healthcare Mobile Apps and Their Use Cases
- How Robots Are Introducing A New Dimension To Healthcare Service Delivery
- Global Top Players in Intraocular Lens (IOL) Market
- Most Promising Applications of Artificial Intelligence (AI) in Healthcare Segment
- How are Nanobots Proving Their Excellence in the Healthcare Industry?
- Top 10 Expected Oncology Drug Launches in 2023
Denali’s Impressive Research Portfolio
Aug 26, 2016 | Reading Time: < 1 minutes
FDA Grants Priority Review to BMS’ Luspatercept; Teva and MedinCell’s Risperidone FDA Approval; Biogens’s QALSODY FDA Accelerated Approval; FDA IND Authorization to Kiromic’s Deltacel; Atsena’s ATSN-201 FDA IND Clearance
FDA Grants Priority Review to Luspatercept for First-line Treatment of Anemia in Lower-risk MDS The FDA has granted priority review to a supplemental biologics license application (sBLA) seeking to expand the current indication of luspatercept-aamt (Reblozyl) to include treatment of anemia in patients with very ...Find More
HUTCHMED’s NDA Submission to FDA for Fruquintinib; Cytokinetics to Discontinue ALS Drug Candidate Following Phase III Trial Failure; Enfortumab Vedotin + Pembrolizumab Approved for Urothelial Carcinoma; Nanoscope Gene Therapy Clears Phase II Retinitis Pigmentosa Trial; FDA Clearance to Cabaletta Bio’s IND Application for CABA-201 for SLE Treatment; European Orphan Drug Designation to Gene Therapy Candidate DB-OTO
HUTCHMED Completes Rolling Submission of NDA to FDA for Fruquintinib HUTCHMED (China) Limited announced the completion of the rolling submission of a New Drug Application ("NDA") to the United States Food and Drug Administration ("FDA") for fruquintinib, its highly selective and potent oral inhibitor of VEGFR-1,...Find More
SpringWorks’s Desmoid Tumors Therapeutic, Nirogacestat; Orphan Drug Designation to AskBio’s AB-1003; Mitsubishi Tanabe’s Phase 3 Trial of RADICAVA ORS in ALS; EU Orphan Drug Designation to Sage Therapeutics’s SAGE-718; FDA Fast Track Status to Biohaven’s Taldefgrobep Alfa
Sage Therapeutics Receives EU Orphan Drug Designation for Huntington's Disease Treatment Candidate Sage Therapeutics declared the European Medicines Agency granted Orphan Drug Designation to SAGE-718 for the treatment of Huntington's disease. SAGE-718 is developing as a potential oral therapy for cognitive disor...Find More
ASCO Conference 2023
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.